Published in Oncogene on June 30, 2008
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol (2009) 4.04
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene (2011) 3.08
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports (2013) 2.47
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol (2015) 1.71
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol (2010) 1.62
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res (2011) 1.57
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology (2010) 1.57
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res (2011) 1.54
Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol (2009) 1.53
HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature (2016) 1.53
Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact (2008) 1.52
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res (2011) 1.51
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells (2011) 1.45
Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer (2009) 1.45
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells. Cancer Cell Int (2016) 1.40
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget (2014) 1.34
Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer (2010) 1.31
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer (2010) 1.31
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J (2014) 1.30
Integrins in mammary-stem-cell biology and breast-cancer progression--a role in cancer stem cells? J Cell Sci (2009) 1.27
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci (2010) 1.23
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer (2010) 1.20
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs (2010) 1.20
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med (2011) 1.17
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res (2012) 1.17
The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol (2011) 1.16
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res (2013) 1.16
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A (2012) 1.14
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell (2015) 1.13
Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One (2010) 1.10
The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells. Oncogene (2013) 1.10
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Breast cancer stem cells: Multiple capacities in tumor metastasis. Cancer Lett (2014) 1.07
Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia (2008) 1.07
Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells. Oncogene (2013) 1.07
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene (2013) 1.07
RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One (2012) 1.06
Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol (2013) 1.05
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene (2014) 1.04
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.04
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res (2013) 1.03
Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget (2014) 1.03
Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol (2015) 1.02
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) (2013) 1.02
Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des (2015) 1.01
Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment. Am J Pathol (2010) 1.01
A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer (2012) 1.00
Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J Biol Chem (2011) 1.00
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene (2011) 1.00
PPARγ maintains ERBB2-positive breast cancer stem cells. Oncogene (2013) 0.99
EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One (2012) 0.99
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci (2011) 0.98
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids (2011) 0.98
Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. J Theor Biol (2010) 0.98
Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer (2010) 0.97
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells (2015) 0.97
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int (2014) 0.96
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog (2011) 0.96
HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med (2012) 0.96
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res (2014) 0.93
Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One (2011) 0.93
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget (2015) 0.93
Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci U S A (2010) 0.93
Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res (2013) 0.92
In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS One (2013) 0.92
Salivary gland cancer stem cells. Oral Oncol (2013) 0.92
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation (1998) 5.43
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat (2007) 3.83
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol Cell Biol (2003) 2.40
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology (2006) 1.39
Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat (1994) 1.11
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res (2005) 1.08
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol (2002) 1.05
Phosphoinositide 3-kinases and regulation of embryonic stem cell fate. Biochem Soc Trans (2007) 1.04
The role of ErbB inhibitors in trastuzumab resistance. Oncologist (2004) 1.01
[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]. Bull Cancer (1999) 0.92
Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells. J Cell Biol (1983) 3.02
Extracellular matrix promotes mammary epithelial growth and differentiation in vitro. Proc Natl Acad Sci U S A (1982) 2.72
Effects of inhibition of basement membrane collagen deposition on rat mammary gland development. Dev Biol (1980) 1.79
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ (2008) 1.76
Regulation of rat mammary gene expression by extracellular matrix components. Exp Cell Res (1987) 1.75
Connectin: cell surface protein that binds both laminin and actin. Proc Natl Acad Sci U S A (1983) 1.71
Basement membrane collagen requirements for attachment and growth of mammary epithelium. Exp Cell Res (1979) 1.52
Symmetric division of cancer stem cells--a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther (2007) 1.44
Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res (1979) 1.44
Hormonal requirements for basement membrane collagen deposition by cultured rat mammary epithelium. Lab Invest (1979) 1.20
Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures. Blood (1983) 1.20
Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene (2011) 1.19
Macrophages express a plasma membrane receptor for basement membrane laminin. Am J Pathol (1986) 1.19
Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat (1999) 1.18
The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behav Res Ther (2005) 1.16
Haemonectin, a bone marrow adhesion protein specific for cells of granulocyte lineage. Nature (1987) 1.15
Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res (1995) 1.07
Metastatic potential of murine fibrosarcoma cells is influenced by cell surface laminin. Int J Cancer (1984) 1.01
Human neutrophil laminin receptors: activation-dependent receptor expression. J Immunol (1987) 1.01
Clustering of cell surface laminin enhances its association with the cytoskeleton. Exp Cell Res (1986) 1.00
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol (1999) 0.99
Inhibition of collagen deposition in the extracellular matrix prevents the establishment of a stroma supportive of hematopoiesis in long-term murine bone marrow cultures. J Clin Invest (1985) 0.98
Regulation of mammary differentiation by the extracellular matrix. Environ Health Perspect (1989) 0.97
Laminin promotes the oxidative burst in human neutrophils via increased chemoattractant receptor expression. J Immunol (1989) 0.93
Unsaturated fatty acid requirements for growth and survival of a rat mammary tumor cell line. Cancer Res (1978) 0.93
cDNA cloning and molecular characterization of MSE55, a novel human serum constituent protein that displays bone marrow stromal/endothelial cell-specific expression. J Biol Chem (1992) 0.93
Extracellular matrix and the hematopoietic microenvironment. J Lab Clin Med (1988) 0.92
Role of the cytoskeleton in laminin induced mammary gene expression. J Cell Physiol (1988) 0.91
Macrophages express cell surface laminin. Exp Cell Res (1983) 0.91
bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res (1996) 0.91
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol (2000) 0.90
Extracellular matrix promotes the growth and differentiation of murine hematopoietic cells in vitro. J Clin Invest (1985) 0.90
Relationship of hair dye use, benign breast disease, and breast cancer. J Natl Cancer Inst (1980) 0.89
Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol (2010) 0.88
Identification of a laminin-like substance on the surface of high-malignant murine fibrosarcoma cells. J Cell Sci (1984) 0.85
Fetal expression of hemonectin: an extracellular matrix hematopoietic cytoadhesion molecule. Blood (1990) 0.84
Differential regulation of apoptosis in normal versus transformed mammary epithelium by lutein and retinoic acid. Cancer Epidemiol Biomarkers Prev (2000) 0.84
A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther (2000) 0.83
Genomic analysis of the 67-kDa laminin receptor in normal and pathological tissues: circumstantial evidence for retroposon features. Genomics (1991) 0.81
Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science (1989) 0.81
Sensitivity of N-nitrosomethylurea-induced rat mammary tumors to cis-hydroxyproline, an inhibitor of collagen production. Cancer Res (1981) 0.80
Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells. Biochem Pharmacol (1999) 0.80
A potential role for the extracellular matrix glycoprotein laminin in macrophage-tumor-cell interactions. Int J Cancer (1985) 0.80
Interaction of rat mammary epithelium with extracellular matrix components. Prog Clin Biol Res (1984) 0.80
Posttranscriptional regulation of alpha-casein mRNA accumulation by laminin. Exp Cell Res (1992) 0.79
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). Ecancermedicalscience (2010) 0.79
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer. Curr Oncol (2013) 0.79
Immunolymphoscintigraphy in breast cancer: evaluation using 131I-labeled monoclonal antibody B72.3. Nucl Med Biol (1998) 0.78
[Blood coagulation changes in patients with post-splenectomy persistent thrombocytosis]. Chir Ital (2001) 0.78
Radioimmunoguided surgery in colorectal cancer: a 6-year experience with four different technical solutions. Semin Surg Oncol (1998) 0.78
Developmental regulation of granulocytic cell binding to hemonectin. Blood (1990) 0.77
Respiration and gene expression in germinating ascospores of Neurospora tetrasperma. FEMS Microbiol Lett (1992) 0.77
Blocking basement membrane collagen deposition inhibits the growth of 7,12-dimethylbenzanthracene-induced rat mammary tumors. Cancer Lett (1981) 0.77
Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer. Minerva Chir (2008) 0.77
A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells. Neoplasia (2000) 0.77
Heat shock gene expression in germinating ascospores of Neurospora tetrasperma. FEMS Microbiol Lett (1992) 0.77
cDNA cloning and genomic analysis of a new multigene family sharing common phylogenetic and expression profiles with the laminin receptor gene. Biochem Biophys Res Commun (1992) 0.77
Swedish nurses' estimation of fatigue as a symptom in cancer patients--report of a questionnaire. Eur J Cancer Care (Engl) (1997) 0.77
Targeting cancer cell death with a bcl-XS adenovirus. Springer Semin Immunopathol (1998) 0.76
Murine granulocytic cell adhesion to bone marrow hemonectin is mediated by mannose and galactose. Blood (1995) 0.76
A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells. Hum Gene Ther (1998) 0.75
Histochemical detection of gamma aminobutyric acid (GABA) degradative enzymes in the Purkinje cell population of old rat cerebellum. Basic Appl Histochem (1979) 0.75
[Rectal prolapse]. J Chir (Paris) (2000) 0.75
Collagen-production inhibitors evaluated as antitumor agents. J Natl Cancer Inst (1985) 0.75
[Axillary lymph node excision]. J Chir (Paris) (1998) 0.75
A bcl-x(S) adenovirus demonstrates therapeutic efficacy in an ascites model of human breast cancer. J Soc Gynecol Investig (2000) 0.75
Plurifocal breast cancer and double lymphatic spread. G Chir (2008) 0.75
Sentinel lymph node biopsy in the treatment of breast cancer. Experience in 527 cases. Minerva Chir (2007) 0.75
[Breast-conserving surgery in breast cancer]. G Chir (2006) 0.75
Lupus mastitis in systemic lupus erythematosus: a rare condition requiring a minimally invasive diagnostic approach. Int J Immunopathol Pharmacol (2012) 0.75
[Ductal carcinoma in situ of the breast]. G Chir (2006) 0.75
Distribution of pemphigus and pemphigoid antigens, laminin, and type IV collagen in corneal epithelium. Invest Ophthalmol Vis Sci (1981) 0.75
Kinetics of layer-thinning transitions in overheated smectic films. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (2000) 0.75
[The integrated radiosurgical treatment of rectal cancer]. Ann Ital Chir (1999) 0.75